FIGS, Inc. filings document the company’s healthcare apparel business, operating results and public-company governance. Form 8-K reports furnish earnings releases and Regulation FD presentations covering net revenues, scrubwear and non-scrubwear categories, U.S. and international sales, active customer measures, average order value, gross margin, operating expenses and outlook disclosures.
The company’s proxy materials address board matters, executive compensation, equity awards and annual meeting governance. Other current reports disclose material agreements, including office lease arrangements related to corporate facilities. Together, FIGS’ regulatory filings describe the business economics, capital and compensation structures, governance practices and material events of a direct-to-consumer healthcare apparel issuer.
FIGS, Inc. filed a Form 144 signaling an intended sale of 99,834 Class A common shares through broker E*TRADE on or about 08/04/2025. The shares were acquired on 08/01/2025 upon vesting of Restricted Stock Units granted under the company’s 2021 Equity Incentive Award Plan. The planned sale carries an aggregate market value of $617,972.46, implying an average price of roughly $6.19 per share.
The transaction represents approximately 0.06% of FIGS’ 154,267,492 shares outstanding. No prior sales were reported in the past three months, and the filer affirms awareness of no undisclosed adverse information. The notice contains no earnings data, financial guidance, or additional corporate developments.